| Wang and Jankovic, 1998*5
|
Mention |
|
1/1 |
Patient report |
| Micheli et al., 2002.6
|
Case report |
2.5 MU in 5 sites (12.5 U) at 12 wk intervals |
1/1 |
Patient report |
| Borodic and Acquadro, 2002.7
|
Case series |
30-50 U |
8/11 |
Patient report |
| Piovesan et al., 2005.4
|
Open-label trial |
6.45-9.11 U per branch (3.3 U/cm2) |
13/13 |
Pain area, p < 0.0001 (at 60 days); VAS, p = NR |
| Türk et al., 2005.9
|
Open-label trial |
50 U in 2 sites (BoNT/A) |
8/8 |
VAS, p = 0.011 and Frequency, p = 0.012 (at 1st wk, 2nd mo, 6thmo) |
| Allam et al., 2005.8
|
Case report |
2 U in 8 points (16 U) (BoNT/A) |
1/1 |
VAS, p = NR |
| Boscá-Blasco et al., 2006*.11
|
Case series |
17.5 U at 6 mo intervals |
4/4 |
PAS, p = NR |
| Volcy et al., 2006.10
|
Case report |
6-7.5 U at 4 mo intervals |
1/1 |
Patient report |
| Uluduz et al., 2007.12
|
Case report |
75 U at 3 mo intervals |
1/1 |
Patient report |
| Felicio et al., 2007*.13
|
Case report |
100 U at 2 mo intervals |
1/1 |
Patient report |
| Zúñiga et al., 2008.14
|
Open-label trial |
20-50 U (BoNT/A) |
10/12 |
VAS, p = NR and Frequency, p = NR (during 8 wk) |
| Ngeow and Nair, 2010.19
|
Case report |
100 U divided into two sites (BoNT/A) |
1/1 |
Patient report |
| Yoon et al., 2010.38
|
Case report |
10 U (BoNT/A) |
1/1 |
Patient report and current perception threshold measurements at 2 mo |
| Bohluli et al., 2011.20
|
Open-label trial |
50-100 U injected at each trigger zone |
15/15 |
VAS, p < 0.001 and Frequency, p < 0.001 (at 1st wk and 1st mo); Global assessment, p < 0.001 (at 6 mo) |
| Wu et al., 2012.21
|
RCT |
75 U injected at 15 points (BoNT/A) |
15/22 responders |
VAS, p < 0.05 (from 2nd wk to 12th wk); Responders (≥ 50% reduction), p < 0.01; Frequency, p < 0.05 (from 1st wk to12thwk); PGIC, p < 0.01 |
| Shehata et al., 2013.23
|
RCT |
40-60 U (5 U per point) in a “follow the pain method” (BoNT/A) |
Proportion NR |
VAS, p < 0.0001 and Frequency, p < 0.0001 (from 2nd wk to 12th wk); QoL, p < 0.0001 |
| Zúñiga et al., 2013.18
|
RCT |
50 U subcutaneously with additional 10 U in the masseter if there is V3 involvement (BoNT/A) |
Proportion NR |
VAS, p = 0.01 (at 3 mo); Frequency, p = 0.036, 0.01, 0.006 (at 1, 2 and 3 mo respectively); Functional impact (no difference) |
| Li et al., 2014.22
|
Open-label trial |
25-170 U (2.5-5 U per point) (BoNT/A) |
88/88 (at 2 mo) to 34/88 (at 14 mo) |
Responders (≥ 50% reduction), p = NR |
| Zhang et al., 2014.24
|
RCT |
25 U and 75 U at 20 points intradermally and/or submucosally (BoNT/A) |
19/27 (25 U) and 25/29 (75 U) from 1stwk to 8th wk |
VAS, p < 0.017; Responders (≥ 50% reduction), p < 0.017; PGIC, p < 0.017 |
| Total |
1 mention; 7 case reports; 2 case series; 5 open-label trials; 4 RCT |
6 U to 170 U |
213/237 |
Patient report: 8 VAS: 9 PAS: 1 Pain area: 1 Frequency: 6 |
